14 results about "Azithromycin" patented technology

The application discloses a hydroxylamine hydrochloride detection method in azithromycin dry suspension, and relates to the trace detection field. The method uses isoamyl aldehyde as a derivatizing agent, generates isoamyl aldoxime by performing derivatization treatment on a sample to be measured, and then uses N-nitrosodiisopropylamine as an internal standard substance to quantitatively determine the isoamyl aldoxime by using liquid chromatography-tandem mass spectrometry. The detection method adopts an isoamyl aldehyde derivatizing agent-N-nitrosodiisopropylamine internal standard substance system, can correct detection errors caused by factors such as matrix effect, pretreatment loss and derivatization efficiency fluctuation, and improves the accuracy and sensitivity of the trace hydroxylamine hydrochloride detection result, thereby guaranteeing the safety of the medicine.

The present invention discloses a novel stable, single phase aqueous suspension for nasal administration to treat bacterial sinusitis. The composition takes azithromycin dihydrate as an active ingredient, and adopts a suspending agent system to prevent phase separation during storage. Embodiments include a formulation comprising a sorbitan monolaurate, or a combination of chitosan and a sorbitan monolaurate, to maintain the stability of the suspension. The present invention has a variety of advantages, including local delivery of azithromycin to an infected site, which can reduce systemic exposure and associated side effects compared to oral formulations.

An aseptically prepared pharmaceutically acceptable azithromycin premix formulation has a pH value of 5.5 to 7.5, preferably 6.0 to 7.0, more preferably 6.3 to 7.0, even more preferably 6.3 to 6.7, for example about 6.5. Preferred embodiments of the aseptically prepared pharmaceutically acceptable azithromycin premix formulation contain azithromycin, a buffering agent, water and optionally a tonicity adjusting agent and are stable for one month, three months, six months, nine months, twelve months, fifteen months, eighteen months or even twenty-four months, during storage at refrigerated temperatures, such as about 5° C., even without any additional components beyond the azithromycin, the buffering agent, and the optional tonicity adjusting agent in the premix formulation. The pharmaceutically acceptable azithromycin premix formulation may be aseptically filled into a container, preferably a glass or flexible container, to form a sterile pharmaceutical azithromycin premix product which does not undergo terminal sterilization. The azithromycin premix product can be a single use premix which is a sterile, stable and ready-to-use aqueous solution for parenteral administration, for example intravenous (IV) administration such as IV infusion, and requires no dilution prior to parenteral administration.

This invention discloses an azithromycin dispersible tablet preparation system, including a fixed platform, a sliding platform slidably connected to the upper end of the fixed platform, guide rails fixed on the front and rear sides of the left side of the upper end of the sliding platform, and a tableting mold fixed on the upper side between the guide rails. The tableting mold has a mold hole on its upper side. By moving the sliding plate below the tableting mold, the sliding plate can provide support during the tableting of powdered azithromycin. After tableting, the screw is driven by a screw motor to rotate, and the screw is threadedly connected to the sliding plate, causing the sliding plate to move to the right away from directly under the tableting mold. Then, the hydraulic cylinder moves the tableting plate down, pushing the formed azithromycin dispersible tablet onto the sliding platform. Then, the sliding plate moves to the left and slides under the tableting mold, which pushes the azithromycin dispersible tablet on the sliding platform to the right away from directly under the tableting mold. This eliminates the need for manual removal of the formed azithromycin dispersible tablet, saving manpower.

The invention relates to an aptamer for specifically detecting neomycin and application of the aptamer, and belongs to the technical field of detection. Firstly, a novel aptamer (the affinity reaches 1.17 + / -0.32 mu M) with good affinity to neomycin is designed, and the aptamer has no reaction to other interfering antibiotics such as chloramphenicol (CAP), oxytetracycline (OTC), enrofloxacin (ENR), azithromycin (AZT), roxithromycin (RXM) and ciprofloxacin (CIP) and has good specificity. Secondly, two fluorescence signal probes of MOF coated FITC and AgNCs are also synthesized, a ratio type fluorescence sensing system is constructed, high-precision and high-sensitivity detection of the target neomycin is realized through a double-signal ratio, and background signal influence caused by environmental interference and fluorescent dye leakage is effectively eliminated.

An aseptically prepared pharmaceutically acceptable azithromycin premix formulation has a pH value of 5.5 to 7.5, preferably 6.0 to 7.0, more preferably 6.3 to 7.0, even more preferably 6.3 to 6.7, for example about 6.5. Preferred embodiments of the aseptically prepared pharmaceutically acceptable azithromycin premix formulation contain azithromycin, a buffering agent, water and optionally a tonicity adjusting agent and are stable for one month, three months, six months, nine months, twelve months, fifteen months, eighteen months or even twenty-four months, during storage at refrigerated temperatures, such as about 5° C., even without any additional components beyond the azithromycin, the buffering agent, and the optional tonicity adjusting agent in the premix formulation. The pharmaceutically acceptable azithromycin premix formulation may be aseptically filled into a container, preferably a glass or flexible container, to form a sterile pharmaceutical azithromycin premix product which does not undergo terminal sterilization. The azithromycin premix product can be a single use premix which is a sterile, stable and ready-to-use aqueous solution for parenteral administration, for example intravenous (IV) administration such as IV infusion, and requires no dilution prior to parenteral administration.

The application discloses a strain of macrolide antibiotic high-efficiency degradation fungus Trichoderma asperellum TS7-1 and application thereof, and belongs to the technical field of microorganisms. The preservation number of the Trichoderma asperellum TS7-1 is CGMCC No.41372. The strain Trichoderma asperellum TS7-1 (CGMCC No.41372) provided by the application has high-efficiency degradation capacity for various macrolide antibiotics (erythromycin, roxithromycin and azithromycin), and the removal rates of the three antibiotics are all above 85% within 36 hours. The high-concentration antibiotic tolerance, degradation rate and degradation spectrum of the Trichoderma asperellum TS7-1 are obviously superior to those of other strains in the prior art. The Trichoderma asperellum TS7-1 is directly separated from a natural soil body without antibiotic pollution, has no hidden danger of animal and plant pathogenicity, and has no microbial toxicity to degradation products of the macrolide antibiotics, so that secondary pollution is avoided, and excellent environmental safety is achieved.

This invention discloses a method for detecting the bioavailability of antibiotics in soil using continuous solvent extraction-solid phase extraction-liquid chromatography-tandem mass spectrometry. The method first uses continuous solvent extraction to extract the bioactive and extractable antibiotic components from the soil. Then, a solid phase extraction column is used for sample purification. Finally, multiple reaction monitoring (MRM) mode of liquid chromatography-tandem mass spectrometry is used to determine the concentrations of various antibiotics, including chlortetracycline, doxycycline, oxytetracycline, tetracycline, sulfadiazine, sulfadiazine, sulfamethoxazole, ciprofloxacin, enrofloxacin, norfloxacin, ofloxacin, azithromycin, erythromycin, roxithromycin, tylosin, trimethoprim, and lincomycin. This invention combines continuous solvent extraction with solid phase extraction, coupled with liquid chromatography-tandem mass spectrometry detection, to achieve accurate evaluation of trace antibiotic bioavailability under complex matrix conditions.

An aseptically prepared pharmaceutically acceptable azithromycin premix formulation has a pH value of 5.5 to 7.5, preferably 6.0 to 7.0, more preferably 6.3 to 7.0, even more preferably 6.3 to 6.7, for example about 6.5. Preferred embodiments of the aseptically prepared pharmaceutically acceptable azithromycin premix formulation contain azithromycin, a buffering agent, water and optionally a tonicity adjusting agent and are stable for one month, three months, six months, nine months, twelve months, fifteen months, eighteen months or even twenty-four months, during storage at refrigerated temperatures, such as about 5° C., even without any additional components beyond the azithromycin, the buffering agent, and the optional tonicity adjusting agent in the premix formulation. The pharmaceutically acceptable azithromycin premix formulation may be aseptically filled into a container, preferably a glass or flexible container, to form a sterile pharmaceutical azithromycin premix product which does not undergo terminal sterilization. The azithromycin premix product can be a single use premix which is a sterile, stable and ready-to-use aqueous solution for parenteral administration, for example intravenous (IV) administration such as IV infusion, and requires no dilution prior to parenteral administration.

The invention belongs to the technical field of azithromycin fumarate crystal form compounds, and particularly relates to a novel low-hygroscopicity azithromycin fumarate crystal form B and a preparation method thereof. Azithromycin fumarate has high hygroscopicity, and medication safety is affected by improper storage of azithromycin fumarate. In order to overcome the defects in the prior art, the invention provides a novel low-hygroscopicity azithromycin fumarate crystal form B and a preparation method thereof, an azithromycin fumarate crude product is used as a raw material, and the novel crystal form B is formed through ultrasonic induction and pressurization treatment after being dissolved in an alcoholic solution. Through verification, compared with the existing crystal form, the novel crystal form B has lower hygroscopicity and high-temperature stability, and the preparation method has the advantages of simplicity, good reproducibility and easiness in industrial production.

The invention relates to the technical field of biology, in particular to a primer pair, a primer probe composition, a PCR premix, a kit and a method for detecting multiple respiratory pathogens. The invention discloses a primer pair with nucleic acid sequences as shown in SEQ ID NO: 1-2, 4-5, 7-8, 10-11, 13-14, 16-17, 19-20, 22-23, 25-26, 28-29, 31-32, 34-35, 37-38 and 40-41. Aiming at a target respiratory pathogen, a specific amplification primer pair is designed and is matched with a proper probe, so that eight-target joint detection can be realized, and the influence of heme, trimethoprim, sulfamethoxazole, amphotericin B, itraconazole, fluconazole, azithromycin, epinephrine and lidocaine hydrochloride in a detection sample can be avoided in the detection process; the anti-interference performance is good, and cross reaction with rhodococcus equi, candida tropicalis and candida krusei does not exist.

The invention belongs to the technical field of medicine crystallization processes, and particularly relates to a crystallization process of small-particle-size azithromycin fumarate with low solvent residue. In the prior art, azithromycin fumarate is crystallized in an alcohol solvent, which is often accompanied by the residue of an ethanol reagent. The invention provides a crystallization process of azithromycin fumarate, which comprises the following steps: feeding part of fumaric acid into azithromycin, adding an azithromycin fumarate seed crystal, carrying out ultrasonic induced crystallization, continuing feeding fumaric acid, and carrying out vacuum concentration for constant-temperature crystal growing. According to the azithromycin fumarate crystal prepared by the method, the particle size distribution range is 15-30 microns, the ethanol residue is also reduced to 0.5% or below, and the azithromycin fumarate crystal can be directly used for preparation processing, does not need to be purified again, and is a raw material medicine product with high quality and good economic benefits.

The invention belongs to the technical field of environmental microorganisms, and particularly relates to an aerobic denitrifying bacterium and application thereof, the aerobic denitrifying bacterium is Raoultella sp. 752, is preserved in China General Microbiological Culture Collection Center (CGMCC) on July 22, 2025, has the preservation number of CGMCC No.35338, and has the preservation number of CGMCC No.35338; the strain has the capability of synchronously degrading high-concentration AZM and nitrate, has the advantages of high adaptability, simplicity, feasibility and the like, and can be directly used for denitrification treatment of high-concentration AZM-containing wastewater in pharmacy, culture and the like.

The invention relates to a hybridoma cell strain capable of secreting a tildipirosin monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain provided by the invention has good sensitivity and specificity to the tildipirosin, wherein the IC50 value to the tildipirosin is 20 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of tildipirosin, such as erythromycin, streptomycin, azithromycin and spiramycin, and has good specificity, so that low-concentration tildipirosin can be accurately detected.